The case of acute psychotic episode treatment in patient with myasthenia gravis
Article Sidebar
Main Article Content
Abstract
A seventy-one old male patient with no previous Hx of mental disorders including alcohol use and with no family Hx of mental disorders was admitted to psychiatric ward due to acute aggression, agitation, excessive irritability and lack olf sleep. He suferred from myasthenia gravis for years and was treated chronically with ambenonium 20 mg daily. Because of comorbidity of uveitis with macular edema he received treatment with prednisolone 70mg daily. Because of acute psychotic symptoms the treatment with olanzapine up to 20mg/d was introduced without effect. The treatment was switched to haloperidol 10mg/d with gradual improvement of patient’s behaviour. He was discharged from the hospital with indication to continue psychiatric, ohpthalomogic, and neurological outpatient care.
Downloads
Article Details
Copyright (c) 2021 Pajor P, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classifi cation and therapeutic strategies. Lancet Neurol 14: 1023-`1036. Link: https://bit.ly/3z3LkFM
Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21: 687-693. Link: https://bit.ly/3v70J4R
Benatar M, Kaminski H (2012) Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev 12: CD005081. Link: https://bit.ly/3v2nIhE
Mehyar M, Rodrigue F, Tiffany L, Robert P (2012) Medications and Myasthenia Gravis (A Reference for Health Care Professionals), Link: https://bit.ly/3ggsL8H
Dubovsky AN, Arvikar S, Stern TA, Axelrod L (2012) The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics 53: 103-115. Link: https://bit.ly/3wZ9iAa
Verma R, Wolfe GI, Kupersmith MJ (2021) Ocular myasthenia gravis - How effective is low dose prednisone long term? J Neurol Sci 420: 117274. Link: https://bit.ly/3w6VMuj
Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, et al. (2004) Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol 92: 500-505. Link: https://bit.ly/3v0NLWr
Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, et al. (2013) Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother 4: S94- S98. Link: https://bit.ly/2T6RDIb
Wolkowitz OM, Burke H, Epel ES, Reus VI (2009) Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci 1179: 19-40. Link: https://bit.ly/3ipWLlb
Trillenberg P, Katalinic A, Junghanns K, Thern J (2021) Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: An estimation of risk based on reporting frequency. Eur J Neurol. Link: https://bit.ly/3gbRZoQ
She S, Yi W, Zhang B, Zheng Y (2017) Worsening of Myasthenia Gravis After Administration of Antipsychotics for Treatment of Schizophrenia: A Case Report and Review of Literature. J Clin Psychopharmacol 37: 620-622. Link: https://bit.ly/3gxwyyT